Long Yuan

Long Yuan, PHD

Postdoctoral Fellow

Department: HP-ENVIRONMENTAL GLOBAL HLTH
Business Phone: (513) 720-9627
Business Email: yuanlong123@ufl.edu

About Long Yuan

Dr. Long Yuan is a Postdoctoral Associate of the Department of Environmental and Global Health and a member of the Center for Environmental and Human Toxicology. He received his Ph.D in University of Cincinnati in 2020. Before joining the University of Florida, Dr. Yuan was a postdoctoral fellow at the Institute of Computational Comparative Medicine at Kansas State University.

Dr. Yuan’s doctoral training was in pharmacology and pharmacokinetic based on melanoma and breast cancer. Dr. Yuan’s current research has focused on development of a PBPK model for meloxicam in broiler chickens and laying hens, analyzing the pharmacokinetic properties of nanoparticles in animals and humans, implementing machine learning, deep learning and AI approach in simulating drug distribution and nanoparticle properties.

Accomplishments

Risk Assessment SS John Doull Risk Assessment Endowment Award
2020 · Biological Modeling Specialty Section (BMSS), Society of Toxicology

Research Profile

Dr. Yuan’s current research has focused on development of a PBPK model for meloxicam in broiler chickens and laying hens, analyzing the pharmacokinetic properties of nanoparticles in animals and humans, implementing machine learning, deep learning and AI approach in simulating drug distribution and nanoparticle properties.

Publications

2021
Phosphoinositide 3-Kinase (PI3K) Reactive Oxygen Species (ROS)-Activated Prodrug in Combination with Anthracycline Impairs PI3K Signaling, Increases DNA Damage Response and Reduces Breast Cancer Cell Growth
International Journal of Molecular Sciences. 22(4) [DOI] 10.3390/ijms22042088. [PMID] 33669867.
2020
BRAF Mutant Melanoma Adjusts to BRAF/MEK Inhibitors via Dependence on Increased Antioxidant SOD2 and Increased Reactive Oxygen Species Levels
Cancers. 12(6) [DOI] 10.3390/cancers12061661. [PMID] 32585852.
2020
Current Advances in the Treatment of BRAF-Mutant Melanoma
Cancers. 12(2) [DOI] 10.3390/cancers12020482. [PMID] 32092958.
2019
Oxidative Cyclization‐Induced Activation of a Phosphoinositide 3‐Kinase Inhibitor for Enhanced Selectivity of Cancer Chemotherapeutics
ChemMedChem. 14(22):1933-1939 [DOI] 10.1002/cmdc.201900481.
2018
Activating HER3 mutations in breast cancer.
Oncotarget. 9(45):27773-27788 [DOI] 10.18632/oncotarget.25576. [PMID] 29963236.
2018
HER3 signaling and targeted therapy in cancer.
Oncology reviews. 12(1) [DOI] 10.4081/oncol.2018.355. [PMID] 30057690.
2018
Role of Reactive Oxygen Species and Targeted Therapy in Metastatic Melanoma
Cancer Research Frontiers. 4(1):101-130 [DOI] 10.17980/2018.101.
2018
Utilization of Reactive Oxygen Species Targeted Therapy to Prolong the Efficacy of BRAF Inhibitors in Melanoma.
Journal of Cancer. 9(24):4665-4676 [DOI] 10.7150/jca.27295. [PMID] 30588251.
2014
Tumor targeting HPMA-porphyrin-99mTc copolymer molecular imaging agent
Journal of Biomaterials Science, Polymer Edition. 25(18):2066-2079 [DOI] 10.1080/09205063.2014.970064.

Education

Doctor of Philosophy in Pharmaceutical Sciences
2020 · University of Cincinnati, James L. Winkle College of Pharmacy

Contact Details

Phones:
Business:
(513) 720-9627
Emails: